Biotech RadarJobs updated

COMPANY

Kura Oncology

HQ: San Diego, CA source · kuraoncology.com ↗ · West Coast

FDA-approved therapeutic company Clinical Phase 3

11 open jobs · last seen Oct 23, 2026 · 17 sources

Keywords: oncology blood cancers solid tumors Acute Myeloid Leukemia HNSCC AML With Mutated NPM1 KMT2Ar NPM1 Mutation AML Hematologic Malignancy MLL Rearrangement Leukemia Myeloid Leukemia Leukemia, Myeloid, Acute Acute Leukemia Neoplasms by Histologic Type With KMT2A Rearrangements Acute Lymphoblastic Leukemia With NPM1 Mutations Acute Myeloid Leukemia With KMT2A Rearrangements Acute Myeloid Leukemia HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) Solid Tumors With HRAS Alterations Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma Clear Cell Renal Cell Carcinoma Non Clear Cell Renal Cell Carcinoma Mixed Lineage Leukemia Mixed Lineage Acute Leukemia Acute Leukemia of Ambiguous Lineage Mixed Phenotype Acute Leukemia Acute Lymphoblastic Leukemia Mixed Lineage Leukemia Gene Mutation Refractory AML Acute Myeloid Leukemia Recurrent Myeloid Sarcoma Nucleophosmin 1-mutated Acute Myeloid Leukemia Gastrointestinal Stromal Tumor Gastrointestinal Stromal Cancer Gastrointestinal Stromal Neoplasm

Profile checked Oct 10, 2026

11Open jobs17Trials (company is sponsor)1FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Manager/Associate Director, Scientific Communications & PublicationsremoteOct 21, 2026Oct 22, 2026
Oncology Account Manager - DetroitField BasedOct 21, 2026Oct 22, 2026
Manager, Biosample OperationsBoston, Mass or RemoteOct 13, 2026Oct 14, 2026
Manager/Sr. Manager, IR & Corporate CommunicationsSan Diego, CAOct 9, 2026Oct 10, 2026
Senior Director, HR Business PartnerUnited StatesOct 9, 2026Oct 9, 2026

See all 11 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (11 open jobs at last check). source ↗
  2. FDA FDA New drug/biologic (novel): KOMZIFTI (ziftomenib) — NDA220305, Nov 13, 2025. Applicant at approval: Kura Oncology, Inc. source ↗
  3. Trial start Phase 3: Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML source ↗
  4. Trial start Phase 1: A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) source ↗
  5. Trial start Phase 1: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia source ↗
  6. Trial start Phase 1: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors source ↗
  7. Trial start Phase 1: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML source ↗
  8. Trial start Phase 1: Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer source ↗
  9. Trial start Phase 1/Phase 2: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) source ↗
  10. Trial start Phase 1: Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies source ↗
  11. Trial start Phase 1/Phase 2: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia source ↗
  12. Trial start Phase 2: Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy source ↗
  13. Trial start Phase 1: First-in-Human Study of KO-947 in Non-Hematological Malignancies source ↗
  14. Trial start Phase 2: Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia source ↗
  15. Trial start Phase 2: Tipifarnib in Subjects With Myelodysplastic Syndromes source ↗
  16. Trial start Phase 2: Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy source ↗
  17. Trial start II: Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 11

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Manager/Associate Director, Scientific Communications & PublicationsremoteOct 21, 2026Oct 22, 2026Not stated
Oncology Account Manager - DetroitField BasedOct 21, 2026Oct 22, 2026Not stated
Manager, Biosample OperationsBoston, Mass or RemoteOct 13, 2026Oct 14, 2026Mid
Manager/Sr. Manager, IR & Corporate CommunicationsSan Diego, CAOct 9, 2026Oct 10, 2026Mid
Senior Director, HR Business PartnerUnited StatesOct 9, 2026Oct 9, 2026Senior
Director, Clinical Business OperationsBoston, MASep 30, 2026Oct 9, 2026Senior
Clinical Trial AssociateBoston, MASep 30, 2026Oct 9, 2026Entry
Associate Director/Director, Medical & Regulatory WritingRemoteSep 30, 2026Oct 9, 2026Senior
Oncology Account Manager - Indianapolis/KY/ILField BasedSep 15, 2026Oct 9, 2026Mid
Assoc Director/Director, ITremoteSep 11, 2026Oct 9, 2026Senior
CTL/Senior Clinical Trial LeaderBoston, MAAug 21, 2025Oct 9, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 17

RecordTitlePhaseStatusStartPrimary completion
NCT07007312Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPhase 3RecruitingSep 26, 20252031-11 (estimated)
NCT04997902Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Phase 1/Phase 2CompletedDec 7, 2021Aug 29, 2025 (actual)
NCT06001788Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 1RecruitingFeb 22, 20242026-12 (estimated)
NCT05738538Expanded Access to ZiftomenibNot listedAvailableNot listedNot listed
NCT04809233Expanded Access to TipifarnibNot listedAvailableNot listedNot listed
NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPhase 1RecruitingOct 18, 20232027-01 (estimated)
NCT04067336First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaPhase 1/Phase 2Active, not recruitingSep 12, 2019Oct 16, 2028 (estimated)
NCT05735184A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLPhase 1RecruitingJul 18, 20232030-04 (estimated)
NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Phase 1RecruitingMar 27, 20252027-12 (estimated)
NCT02779777Tipifarnib in Subjects With Myelodysplastic SyndromesPhase 2TerminatedJun 1, 2016Aug 28, 2018 (actual)
NCT02807272Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaPhase 2CompletedJan 10, 2017Nov 30, 2020 (actual)
NCT02383927Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsIICompletedMay 13, 2015Dec 14, 2020 (actual)
NCT02464228Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyPhase 2CompletedFeb 25, 2016Mar 31, 2021 (actual)
NCT03719690Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyPhase 2CompletedMar 15, 2019May 2, 2023 (actual)
NCT04865159Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid MalignanciesPhase 1TerminatedMay 6, 2021May 2, 2023 (actual)
NCT05693090Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerPhase 1WithdrawnFeb 1, 2023Jul 27, 2027 (estimated)
NCT03051035First-in-Human Study of KO-947 in Non-Hematological MalignanciesPhase 1TerminatedApr 6, 2017Jun 2, 2020 (actual)

FDA records (last 2 years)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Kura Oncology on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback